The Medical Advisor

OneDayMD • The Medical Advisor A single starting point for exploring OneDayMD's health, wellness, longevity, nutrition, cancer, metabolic medicine, emerging therapies and digital-health research. Quick Answer OneDayMD is an independent health-information and research-synthesis platform covering conventional medicine, integrative health, longevity, nutrition, supplements, metabolic medicine, cancer research, emerging therapies and digital health. This Master Guide is the site's central navigation page: use it to find the right topic hub, then move from a broad guide to the specific evidence, study, therapy, supplement, condition or research question you are investigating. On this page Start Here · Core Health Hubs · Cancer & Oncology · Nutrition & Supplements · Longevity · GLP-1 & Metabolic Health · DMSO ·...

OneDayMD Master Evidence Guide • Updated September 23, 2026 Semaglutide, tirzepatide, oral GLP-1 medicines, retatrutide and the next generation of metabolic therapies have changed the obesity and cardiometabolic treatment landscape. But the phrase “GLP-1 drug” can hide major differences in mechanism, indication, dose, study population and clinical evidence. This master guide organizes the most important clinical trials into an ebook-style reference—from the landmark STEP and SURMOUNT obesity trials to SELECT , FLOW , SUMMIT , ESSENCE , OASIS 4 , ATTAIN-1 , TRIUMPH and the emerging CagriSema program. 2026 update: The field has moved beyond injections alone. Oral semaglutide (Wegovy tablets) and orforglipron (Foundayo) are now U.S. FDA-approved options for weight management, while higher-dose semaglutide (Wegovy HD) has also entered clinical use. Retatrutide remains investigational, despite substantial Phase 3 result...